Skip to content

ArriVent BioPharma

US · AVBP #3057 by market cap Listed 2024
16.89 +1.80 +11.93%
Live - 5344 symbols - heartbeat 140s ago · 2026-10-08 08:38
Pre-market 16.55 -2.01%
After-hours 17.10 +1.24%
Overnight 16.89 0.00%
Market cap
832.81M
P/B
2.27
EPS
-4.32
Reader sentiment Are you bullish or bearish on AVBP?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Alterity Therapeutics (ATHE)
    TipRanks · 2026/8/13
  • Rating change
    Analysts Conflicted on These Healthcare Names: ArriVent BioPharma, Inc. (AVBP), Zimmer Biomet Holdings (ZBH) and Tecan Group AG (OtherTCHBF)
    TipRanks · 2026/8/14
  • Rating change
    Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Protagonist Therapeutics (PTGX) and Resmed (RMD)
    TipRanks · 2026/6/22
  • Rating change
    H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47
    Market Newswire · 2026/8/17
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/9/15
  • Rating change
    BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/7/15
  • Rating change
    A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50
    Market Newswire · 2026/8/14
  • Rating change
    Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/7/22
  • Rating change
    JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/7/6
  • ArriVent BioPharma, Inc. (AVBP) Gets a Buy From Guggenheim
    TipRanks · 2026/9/15
  • Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/9/15
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Kyverna Therapeutics, Inc. (KYTX) and ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/8/14
  • Rating change
    Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40
    Market Newswire · 2026/8/15
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/7/22
  • Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating
    Market Newswire · 2026/9/16
  • Rating change
    LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/7/14
  • Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB), Nuvation Bio (NUVB) and ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/9/15
  • A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $45
    Market Newswire · 2026/9/15
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/7/14
  • Rating change
    A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50
    Market Newswire · 2026/8/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:38:53 · For reference only, not investment advice and not tailored to your situation.